Surgical emergencies in the cancer patient
Surgical emergencies in the cancer patient
Yuman Fong, Rondi Marie Kauffmann, Emily Marcinkowski, Gagandeep Singh, Hans F. Schoellhammer, editors.
- 1 recurso en línea
Incluye referencias bibliográficas e índice
Preface; Foreword; Contents; Contributors; 1: Preoperative Evaluation of the Cancer Patient for Emergency Surgery; Introduction; The American Society of Anesthesiologists' Risk Classification; Preoperative Cardiovascular Risk Assessment; Coronary Artery Disease; Heart Failure; Valvular Heart Disease; Aortic Stenosis; Mitral Stenosis; Aortic Regurgitation and Mitral Regurgitation; Perioperative Fluid Management; Transfusions; Sepsis; Preoperative Pulmonary Evaluation; Airway Management; References; 2: Toxicity of Antineoplastic Therapy and Considerations for Perioperative Care Cancer Outcomes After Transfusions Implications of the Spleen in Regulation of Thrombocyte Counts and Spleen-Based Regulation of the Immune System; Summary; References; 5: Emergency Surgery After Previous Radiation Therapy; Identifying a Previously Irradiated Patient; Radiation Therapy Terminology; Basics of Radiation Exposure, Dose, and Types; Radiation Techniques and Terminology; Biology of Radiation Exposure of Normal Tissues; Skin; Mucosa; Muscles; Lymphatics; Evaluating the Previously Irradiated Patient for Consideration of Surgery; Overall Status of the Patient Early Postoperative Intraperitoneal Chemotherapy (EPOCH or EPIC) Summary; References; 3: Surgical Considerations and Emergencies in the Cancer Patient Receiving Immunotherapy; Introduction; Current Progress of Immunotherapy in Cancer; Overview of Immune Checkpoint Pathways; CTLA4 Axis; PD-1 Axis; Future Pathways of Interest; Current Immune Checkpoint Inhibitors Approved and in Development (Table 3.1); Ipilimumab; Tremelimumab; Nivolumab; Pembrolizumab; MEDI4736; BMS-936559; MPDL3280A; Gastrointestinal Toxicities from Immunotherapy (Table 3.2); CTLA4 Inhibitors Introduction Cytotoxic Agents and Potential Organ Toxicity; Hematologic Toxicity; Cardiac Toxicity; Anthracycline Antitumor Antibiotics; Alkylating Agents; Other Chemotherapeutic Agents with Potential Cardiotoxicity; Pulmonary Toxicity; Antitumor Antibiotics; Renal Toxicity; Platinum Agents; Neurologic Toxicity; Hepatic Toxicity; Specific Considerations in Perioperative Care; Corticosteroids; Agents with Anti-angiogenic Activity; Toxicity of Specific Chemotherapy Regimens; Hyperthermic Intraoperative Intraperitoneal Chemotherapy PD-1/PD-L1 Inhibitors Combining CTLA4 and PD-1/PD-L1 Inhibitors; Therapeutic Strategies for Treatment of Immunotherapy-Induced Colitis; Conclusions; References; 4: Surgery in the Thrombocytopenic and Coagulopathic Patient; Introduction; Background; Thrombocytopenia; Inherited Coagulopathies; Perioperative Acquired Coagulopathy; Therapeutic Anticoagulation; Warfarin; Unfractionated Heparin; Low-Molecular-Weight Heparins; Fondaparinux; Direct Xa Inhibitors; Direct Thrombin Inhibitors; Hemostatic Agents and Devices; Current Recommendations for Transfusions
331944025X 9783319440255
Cáncer--Cirugía
R1 / 2017 EB
Incluye referencias bibliográficas e índice
Preface; Foreword; Contents; Contributors; 1: Preoperative Evaluation of the Cancer Patient for Emergency Surgery; Introduction; The American Society of Anesthesiologists' Risk Classification; Preoperative Cardiovascular Risk Assessment; Coronary Artery Disease; Heart Failure; Valvular Heart Disease; Aortic Stenosis; Mitral Stenosis; Aortic Regurgitation and Mitral Regurgitation; Perioperative Fluid Management; Transfusions; Sepsis; Preoperative Pulmonary Evaluation; Airway Management; References; 2: Toxicity of Antineoplastic Therapy and Considerations for Perioperative Care Cancer Outcomes After Transfusions Implications of the Spleen in Regulation of Thrombocyte Counts and Spleen-Based Regulation of the Immune System; Summary; References; 5: Emergency Surgery After Previous Radiation Therapy; Identifying a Previously Irradiated Patient; Radiation Therapy Terminology; Basics of Radiation Exposure, Dose, and Types; Radiation Techniques and Terminology; Biology of Radiation Exposure of Normal Tissues; Skin; Mucosa; Muscles; Lymphatics; Evaluating the Previously Irradiated Patient for Consideration of Surgery; Overall Status of the Patient Early Postoperative Intraperitoneal Chemotherapy (EPOCH or EPIC) Summary; References; 3: Surgical Considerations and Emergencies in the Cancer Patient Receiving Immunotherapy; Introduction; Current Progress of Immunotherapy in Cancer; Overview of Immune Checkpoint Pathways; CTLA4 Axis; PD-1 Axis; Future Pathways of Interest; Current Immune Checkpoint Inhibitors Approved and in Development (Table 3.1); Ipilimumab; Tremelimumab; Nivolumab; Pembrolizumab; MEDI4736; BMS-936559; MPDL3280A; Gastrointestinal Toxicities from Immunotherapy (Table 3.2); CTLA4 Inhibitors Introduction Cytotoxic Agents and Potential Organ Toxicity; Hematologic Toxicity; Cardiac Toxicity; Anthracycline Antitumor Antibiotics; Alkylating Agents; Other Chemotherapeutic Agents with Potential Cardiotoxicity; Pulmonary Toxicity; Antitumor Antibiotics; Renal Toxicity; Platinum Agents; Neurologic Toxicity; Hepatic Toxicity; Specific Considerations in Perioperative Care; Corticosteroids; Agents with Anti-angiogenic Activity; Toxicity of Specific Chemotherapy Regimens; Hyperthermic Intraoperative Intraperitoneal Chemotherapy PD-1/PD-L1 Inhibitors Combining CTLA4 and PD-1/PD-L1 Inhibitors; Therapeutic Strategies for Treatment of Immunotherapy-Induced Colitis; Conclusions; References; 4: Surgery in the Thrombocytopenic and Coagulopathic Patient; Introduction; Background; Thrombocytopenia; Inherited Coagulopathies; Perioperative Acquired Coagulopathy; Therapeutic Anticoagulation; Warfarin; Unfractionated Heparin; Low-Molecular-Weight Heparins; Fondaparinux; Direct Xa Inhibitors; Direct Thrombin Inhibitors; Hemostatic Agents and Devices; Current Recommendations for Transfusions
331944025X 9783319440255
Cáncer--Cirugía
R1 / 2017 EB